ACDN-01 longer-term retinal outcomes
The STELLAR program evaluates safety and preliminary efficacy after one subretinal ACDN-01 injection. Longer follow-up is distinct from its already announced first-in-human safety presentation.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- The twelve-month threshold is an authored research predicate, not a company-announced presentation commitment; specify the exact endpoint.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Longer-term follow-up candidate — date unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links ascidian-tx.com. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof.
Potential outcome market
Will Ascidian publicly report at least twelve-month treated-patient retinal outcomes from STELLAR by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.